(VIANEWS) – Energy Transfer (ET), Astrazeneca (AZN), Neurocrine Biosciences (NBIX) are the highest sales growth and return on equity stocks on this list.

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. Energy Transfer (ET)

58.3% sales growth and 14.29% return on equity

Energy Transfer’s sales growth this year is expected to be 60.2% and 1% for next year.

Year-on-year quarterly revenue growth grew by 105.8%, now sitting on 52.08B for the twelve trailing months.

Volume

Today’s last reported volume for Energy Transfer is 9500840 which is 51.13% below its average volume of 19443900.

Energy Transfer’s sales growth is a negative 0% for the current quarter and 58.3% for the next. The company’s growth estimates for the current quarter and the next is 196.6% and 57.9%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.29%.

Volatility

Energy Transfer’s last day, last week, and last month’s current intraday variation average was 2.79%, 2.94%, and 2.33%, respectively.

Energy Transfer’s highest amplitude of average volatility was 1.84% (day), 2.87% (last week), and 3.97% (last month), respectively.

Energy Transfer’s Stock Yearly Top and Bottom Value

Energy Transfer’s stock is valued at $8.16 at 15:22 EST, way under its 52-week high of $11.55 and way above its 52-week low of $5.11.

Energy Transfer’s Moving Average

Energy Transfer’s value is way under its 50-day moving average of $9.70 and way below its 200-day moving average of $9.81.

Previous days news about Energy Transfer(ET)

  • A bearish sign appears on energy transfer's chart. According to Benzinga on Friday, 10 December, "If history is any guide, there may be trouble ahead for shares of Energy Transfer (NYSE:ET). "

2. Astrazeneca (AZN)

43% sales growth and 25.67% return on equity

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide.

Astrazeneca’s sales growth this year is expected to be 35.1% and 15.7% for next year.

Year-on-year quarterly revenue growth grew by 31%, now sitting on 29.53B for the twelve trailing months.

Volume

Today’s last reported volume for Astrazeneca is 2742260 which is 48.12% below its average volume of 5286160.

Astrazeneca’s sales growth for the next quarter is 43%. The company’s growth estimates for the ongoing quarter and the next is 40.4% and 45.3%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 25.67%.

Volatility

Astrazeneca’s last day, last week, and last month’s current intraday variation average was 0.89%, 1.01%, and 0.88%, respectively.

Astrazeneca’s highest amplitude of average volatility was 0.99% (day), 0.92% (last week), and 1.20% (last month), respectively.

Astrazeneca’s Stock Yearly Top and Bottom Value

Astrazeneca’s stock is valued at $54.97 at 15:22 EST, way under its 52-week high of $64.21 and way above its 52-week low of $46.48.

Astrazeneca’s Moving Average

Astrazeneca’s value is under its 50-day moving average of $61.00 and under its 200-day moving average of $58.24.

3. Neurocrine Biosciences (NBIX)

30.2% sales growth and 42.19% return on equity

Neurocrine Biosciences, Inc., a neuroscience-focused biopharmaceutical company, discovers, develops, and delivers various treatments for people with neurological, endocrine, and psychiatric disorders.

Neurocrine Biosciences’s sales growth this year is expected to be 9% and 23.4% for next year.

Year-on-year quarterly revenue growth declined by 0.2%, now sitting on 1.05B for the twelve trailing months.

Volume

Today’s last reported volume for Neurocrine Biosciences is 775507 which is 8.85% above its average volume of 712428.

Neurocrine Biosciences’s sales growth for the next quarter is 30.2%. The company’s growth estimates for the ongoing quarter and the next is 193.5% and negative -80.2%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 42.19%.

Volatility

Neurocrine Biosciences’s last day, last week, and last month’s current intraday variation average was 1.20%, 1.77%, and 1.25%, respectively.

Neurocrine Biosciences’s highest amplitude of average volatility was 3.02% (day), 4.63% (last week), and 3.36% (last month), respectively.

Neurocrine Biosciences’s Stock Yearly Top and Bottom Value

Neurocrine Biosciences’s stock is valued at $79.68 at 15:22 EST, way below its 52-week high of $120.27 and higher than its 52-week low of $79.01.

Neurocrine Biosciences’s Moving Average

Neurocrine Biosciences’s value is way below its 50-day moving average of $95.40 and way under its 200-day moving average of $95.52.

4. Tecnoglass (TGLS)

28.4% sales growth and 33.03% return on equity

Tecnoglass Inc., through its subsidiaries, manufactures, supplies, and installs architectural glass, windows, and associated aluminum products for the commercial and residential construction industries in North, Central, and South America.

Tecnoglass’s sales growth this year is expected to be 31.1% and 13.8% for next year.

Year-on-year quarterly revenue growth grew by 26.2%, now sitting on 465.38M for the twelve trailing months.

Volume

Today’s last reported volume for Tecnoglass is 383027 which is 25.32% above its average volume of 305631.

Tecnoglass’s sales growth for the next quarter is 28.4%. The company’s growth estimates for the current quarter and the next is 77.3% and 8.6%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 33.03%.

Volatility

Tecnoglass’s last day, last week, and last month’s current intraday variation average was 1.73%, 2.89%, and 2.41%, respectively.

Tecnoglass’s highest amplitude of average volatility was 4.41% (day), 7.04% (last week), and 6.79% (last month), respectively.

Tecnoglass’s Stock Yearly Top and Bottom Value

Tecnoglass’s stock is valued at $31.23 at 15:22 EST, way under its 52-week high of $34.90 and way above its 52-week low of $5.48.

Tecnoglass’s Moving Average

Tecnoglass’s worth is higher than its 50-day moving average of $28.45 and way above its 200-day moving average of $19.94.

Previous days news about Tecnoglass(TGLS)

  • Hagens berman, national trial attorneys, encourages tecnoglass inc. (tgls) investors who suffered significant losses to contact firm's attorneys, firm investigating possible securities law violations. According to Benzinga on Friday, 10 December, "We’re focused on investors’ losses and whether Tecnoglass and its management may have misled investors about the company’s true financial condition and other matters," said Reed Kathrein, the Hagens Berman partner leading the investigation.", "Whistleblowers: Persons with non-public information regarding Tecnoglass should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. "
  • Tecnoglass alert: bragar eagel & squire, p.c. is investigating tecnoglass inc. on behalf of tecnoglass stockholders and encourages investors to contact the firm. According to Benzinga on Saturday, 11 December, "Our investigation concerns whether Tecnoglass has violated the federal securities laws and/or engaged in other unlawful business practices.", "NEW YORK, Dec. 10, 2021 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Tecnoglass Inc. ("Tecnoglass" or the "Company") (NASDAQ:TGLS) on behalf of Tecnoglass stockholders. "
  • Investigation alert: kessler topaz meltzer & check, LLP is investigating securities fraud claims on behalf of tecnoglass inc. (nasdaq: tgls) investors. According to Business Insider on Saturday, 11 December, "If you are a Tecnoglass investor and would like to learn more about our investigation, please CLICK HERE to fill out our online form or contact Kessler Topaz Meltzer & Check, LLP: James Maro, Esq. ", "Following this news, Tecnoglass shares fell over 40% in early morning trading on December 9, 2021."

5. Lakeland Bancorp (LBAI)

26.8% sales growth and 11.7% return on equity

Lakeland Bancorp, Inc. operates as the bank holding company for Lakeland Bank that provides various banking products and services for individuals and small to medium sized businesses.

Lakeland Bancorp’s sales growth this year is anticipated to be 9.7% and 28% for next year.

Year-on-year quarterly revenue growth grew by 32.6%, now sitting on 264.99M for the twelve trailing months.

Volume

Today’s last reported volume for Lakeland Bancorp is 98390 which is 31.44% below its average volume of 143517.

Lakeland Bancorp’s sales growth for the next quarter is 26.8%. The company’s growth estimates for the ongoing quarter and the next is 13.5% and negative -17.8%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.7%.

Volatility

Lakeland Bancorp’s last day, last week, and last month’s current intraday variation average was 1.66%, 1.29%, and 1.24%, respectively.

Lakeland Bancorp’s highest amplitude of average volatility was 2.39% (day), 2.95% (last week), and 2.29% (last month), respectively.

Lakeland Bancorp’s Stock Yearly Top and Bottom Value

Lakeland Bancorp’s stock is valued at $18.09 at 15:22 EST, under its 52-week high of $19.43 and way above its 52-week low of $12.13.

Lakeland Bancorp’s Moving Average

Lakeland Bancorp’s worth is under its 50-day moving average of $18.30 and above its 200-day moving average of $17.57.

6. Moelis & Company (MC)

23.6% sales growth and 101.03% return on equity

Moelis & Company, an investment bank, provides strategic and financial advisory services in the United States and internationally.

Moelis & Company’s sales growth this year is anticipated to be 66.9% and a negative 4.9% for next year.

Year-on-year quarterly revenue growth grew by 136.4%, now sitting on 1.54B for the twelve trailing months.

Volume

Today’s last reported volume for Moelis & Company is 434954 which is 18.13% above its average volume of 368185.

News about Moelis & Company(MC) today

  • According to today’s article on Benzinga, "Cantor Fitzgerald & Co. and Moelis & Company LLC are acting as the book-running managers of the offering. "

Moelis & Company’s sales growth for the next quarter is 23.6%. The company’s growth estimates for the current quarter and the next is a negative 26.1% and 7.8%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 101.03%.

Volatility

Moelis & Company’s last day, last week, and last month’s current intraday variation average was 0.82%, 1.19%, and 1.65%, respectively.

Moelis & Company’s highest amplitude of average volatility was 2.90% (day), 2.29% (last week), and 2.99% (last month), respectively.

Moelis & Company’s Stock Yearly Top and Bottom Value

Moelis & Company’s stock is valued at $1.01 at 15:22 EST, way under its 52-week low of $39.25.

Moelis & Company’s Moving Average

Moelis & Company’s worth is way below its 50-day moving average of $68.41 and way below its 200-day moving average of $59.33.

7. Affiliated Managers Group (AMG)

10.6% sales growth and 20.24% return on equity

Affiliated Managers Group, Inc., through its affiliates, operates as an asset management company providing investment management services to mutual funds, institutional clients, and high net worth individuals in the United States.

Affiliated Managers Group’s sales growth this year is anticipated to be 16.2% and 11.2% for next year.

Year-on-year quarterly revenue growth grew by 16.2%, now sitting on 2.27B for the twelve trailing months.

Volume

Today’s last reported volume for Affiliated Managers Group is 227109 which is 15.37% above its average volume of 196842.

Affiliated Managers Group’s sales growth for the next quarter is 10.6%. The company’s growth estimates for the present quarter and the next is 36.3% and 15%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 20.24%.

Volatility

Affiliated Managers Group’s last day, last week, and last month’s current intraday variation average was 2.32%, 1.89%, and 1.72%, respectively.

Affiliated Managers Group’s highest amplitude of average volatility was 2.67% (day), 2.70% (last week), and 2.79% (last month), respectively.

Affiliated Managers Group’s Stock Yearly Top and Bottom Value

Affiliated Managers Group’s stock is valued at $161.67 at 15:22 EST, way under its 52-week high of $191.62 and way higher than its 52-week low of $96.03.

Affiliated Managers Group’s Moving Average

Affiliated Managers Group’s value is under its 50-day moving average of $169.68 and under its 200-day moving average of $162.20.

LEAVE A REPLY

Please enter your comment!
Please enter your name here